Sort   by:  
 Page size 
MetabolomicsThe Poly (ADP-Ribose) Polymerase inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells
Breast tumors are characterized into different subtypes based on their surface marker expression, which affects their prognosis and treatment. For example, triple negative breast cancer cells (ER-/PR-/Her2-) show reduced susceptibility towards radiotherapy and chemotherapeutic agents. Poly (ADP-ribo...
2016-11-07 | MTBLS337 | MetaboLights
MetabolomicsCE-MS Metabolomic and LC-MS Proteomic Analyses of Breast Cancer Exosomes Reveal Alterations in Purine and Carnitine Metabolism

A nano sheath-flow capillary electrophoresis mass spectrometry (CE-MS) system with electrospray ionization was used to profile cationic metabolite cargo in exosomes secreted by non-tumorigenic MCF-10A and tumorigenic MDA-MB-231 breast epithelial cells. CE-MS-based metabolomics revealed increased ...

2024-11-14 | MTBLS11190 | MetaboLights
MetabolomicsMetabolomics revealed the influence of breast cancer on lymphatic endothelial cell metabolism, metabolic crosstalk, and lymphangiogenic signaling in co-culture

Breast cancer metastasis occurs via blood and lymphatic vessels. Breast cancer cells 'educate' lymphatic endothelial cells (LECs) to support tumor vascularization and growth. However, despite known metabolic alterations in breast cancer, it remains unclear how lymphatic endothelial cell metabolis...

2024-06-25 | MTBLS859 | MetaboLights
MetabolomicsNormalization strategies for lipidome data in cell line panels & Distinct lipidomic profiles in breast cancer cell lines relate to proliferation and EMT phenotypes

Sample collection can significantly affect measurements of relative lipid concentrations in cell line panels, hiding intrinsic biological properties of interest between cell lines. Most quality control steps in lipidomic data analysis focus on controlling technical variation. Correcting for the t...

2025-08-07 | MTBLS9493 | MetaboLights
MetabolomicsOrganotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations
BACKGROUND: Ductal carcinoma in situ (DCIS) is the earliest stage of breast cancer. During DCIS, tumor cells remain inside the mammary duct, growing under a microenvironment characterized by hypoxia, nutrient starvation, and waste product accumulation; this harsh microenvironment promotes genomic in...
2019-02-08 | MTBLS669 | MetaboLights
MetabolomicsMetabolic memory underlying minimal residual disease in breast cancer

Tumor relapse from treatment-resistant cells (minimal residual disease, MRD) underlies most breast cancer related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive. Here we integrated multi-omics data from a tractable organoid system with a metabol...

2021-09-14 | MTBLS1507 | MetaboLights
TranscriptomicsEpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.
Introduction: The Epithelial Cell Adhesion Molecule (EpCAM) has been shown to be strongly expressed in human breast cancer and cancer stem cells and its overexpression has been supposed to support tumor progression and metastasis. However, effects of EpCAM overexpression on normal breast epithelial ...
ORGANISM(S): Homo sapiens 
2013-06-13 | E-GEOD-39071 | biostudies-arrayexpress
TranscriptomicsAn EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.
Regulation of cell-cell junction formation and regulation of cell migration were enriched among EMT (Epithelial-Mesenchymal Transition)-associated alternatively splicing events. Our analysis suggested that most EMT-associated alternative splicing events are regulated by one or more members of the RB...
ORGANISM(S): Homo sapiens 
2011-07-15 | E-GEOD-30290 | biostudies-arrayexpress
MetabolomicsMulti-omics characterization of acquired Olaparib resistance in BRCA1 and BRCA2 mutant breast cancer cell lines
Poly (ADP-ribose) polymerase inhibitors (PARPi) are widely used as targeted therapies against breast cancers with BRCA mutations. However, the development of resistance to PARPi poses a significant challenge for long-term efficacy of these therapies, warranting further understanding of mechanisms of...
2026-05-11 | MTBLS12109 | MetaboLights
MetabolomicsSingle-cell lipidomic analysis of the Epithelial-Mesenchymal Transition (EMT) using MALDI-MSI

EMT is a metastasis-promoting process whose heterogeneity has been extensively studied at a gene expression level. EMT also involves reprogramming of lipid metabolism, however there has been little focus on heterogeneity on the lipid level. Here, we use MALDI-MSI to determine the levels of variou...

2026-04-15 | MTBLS12650 | MetaboLights
Sort   by:  
 Page size